Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Rhea-AI Summary

Phathom Pharmaceuticals (NASDAQ: PHAT) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 1, 2025, at 8:00 am EDT. The company will host a live webcast accessible through their investor relations website, with a recording available for 90 days afterward.

Phathom specializes in gastrointestinal disease treatments and markets VOQUEZNA® (vonoprazan) tablets in the United States. Their product lineup includes treatments for:

• Non-Erosive GERD heartburn relief in adults
• Healing and maintenance of Erosive GERD in adults
• H. pylori infection treatment through VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK®

• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT

FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update.

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc. 
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

FAQ

When will Phathom Pharmaceuticals (PHAT) release Q1 2025 earnings?

Phathom Pharmaceuticals will release Q1 2025 earnings on Thursday, May 1, 2025, at 8:00 am EDT via a live webcast.

How can investors access Phathom Pharmaceuticals' (PHAT) Q1 2025 earnings call?

Investors can access the webcast through the Events & Presentations section of Phathom's website at investors.phathompharma.com. A recording will be available for 90 days.

What treatments does Phathom Pharmaceuticals (PHAT) currently market in the US?

Phathom markets VOQUEZNA® (vonoprazan) tablets for GERD treatment and VOQUEZNA® TRIPLE PAK® and DUAL PAK® for H. pylori infection in adults.

What medical conditions does VOQUEZNA treat?

VOQUEZNA treats Non-Erosive GERD heartburn, Erosive GERD healing and maintenance, and H. pylori infection in adults.